```
=> fil cap
FILE 'CAPLUS' ENTERED AT 14:30:46 ON 17 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 17 Dec 2008  VOL 149 ISS 25
FILE LAST UPDATED: 16 Dec 2008  (20081216/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> d que l16
L1                STR
```




```
VAR G1=H/OH
VAR G2=CH2/O/NH/23
VAR G3=PH/25/28/31/34/37
VAR G4=X/CN/45/46/48/50
VAR G5=C/N
NODE ATTRIBUTES:
```

```
CONNECT IS E3  RC AT   1
CONNECT IS E2  RC AT   2
CONNECT IS E2  RC AT   3
CONNECT IS E2  RC AT   5
CONNECT IS E2  RC AT   6
CONNECT IS E2  RC AT   7
CONNECT IS E2  RC AT   9
CONNECT IS E2  RC AT  10
CONNECT IS E2  RC AT  12
CONNECT IS E2  RC AT  13
CONNECT IS E1  RC AT  24
CONNECT IS E2  RC AT  25
CONNECT IS E3  RC AT  28
CONNECT IS E4  RC AT  31
CONNECT IS E5  RC AT  34
CONNECT IS E6  RC AT  37
CONNECT IS E1  RC AT  45
CONNECT IS E1  RC AT  49
DEFAULT MLEVEL IS ATOM
GGCAT   IS LOC  SAT  AT  24
GGCAT   IS MCY  UNS  AT  25
GGCAT   IS MCY  UNS  AT  28
GGCAT   IS MCY  UNS  AT  31
GGCAT   IS MCY  UNS  AT  34
GGCAT   IS MCY  UNS  AT  37
GGCAT   IS LOC  SAT  AT  45
GGCAT   IS LOC  SAT  AT  46
GGCAT   IS LOC  SAT  AT  49
GGCAT   IS LOC  SAT  AT  51
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E6 C  AT  25
ECOUNT  IS E6 C  AT  28
ECOUNT  IS E6 C  AT  31
ECOUNT  IS E6 C  AT  34
ECOUNT  IS E6 C  AT  37

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  52

STEREO ATTRIBUTES: NONE
L3          149 SEA FILE=REGISTRY SSS FUL L1
L8              STR
```




```
REP G1=(0-2) A
VAR G2=H/11/12
NODE ATTRIBUTES:
CONNECT IS E1  RC AT  11
DEFAULT MLEVEL IS ATOM
GGCAT   IS SAT  AT  11
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS UNLIMITED  AT   2  3  4
```

```
GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  14

STEREO ATTRIBUTES: NONE
L10         138 SEA FILE=REGISTRY SUB=L3 SSS FUL L8
L16           4 SEA FILE=CAPLUS SPE=ON  ABB=ON  PLU=ON  L10


=> fil wpix
FILE 'WPIX' ENTERED AT 14:30:53 ON 17 DEC 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE LAST UPDATED:          12 DEC 2008   <20081212/UP>
MOST RECENT UPDATE:           200880      <200880/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.2 million chemical structures in DCR <<<

>>> IPC Reform backfile reclassifications have been loaded to end of
    September 2008. No update date (UP) has been created for the
    reclassified documents, but they can be identified by 20060101/UPIC,
    and 20061231/UPIC, 20070601/UPIC, 20071001/UPIC, 20071130/UPIC,
    20080401/UPIC, 20080701/UPIC and 20081001/UPIC.
    ECLA reclassifications to mid August and US national classification
    mid September 2008 have also been loaded. Update dates 20080401,
    20080701 and 20081001/UPEC and /UPNC have been assigned to these. <<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomsonreuters.com/support/patents/coverage/latestupdates/

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/DWPIAnaVist2_0608.html

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<


=> d que l13
L1              STR
```



```
VAR G1=H/OH
VAR G2=CH2/O/NH/23
VAR G3=PH/25/28/31/34/37
VAR G4=X/CN/45/46/48/50
VAR G5=C/N
NODE ATTRIBUTES:
CONNECT IS E3  RC AT   1
CONNECT IS E2  RC AT   2
CONNECT IS E2  RC AT   3
CONNECT IS E2  RC AT   5
CONNECT IS E2  RC AT   6
CONNECT IS E2  RC AT   7
CONNECT IS E2  RC AT   9
CONNECT IS E2  RC AT  10
CONNECT IS E2  RC AT  12
CONNECT IS E2  RC AT  13
CONNECT IS E1  RC AT  24
CONNECT IS E2  RC AT  25
CONNECT IS E3  RC AT  28
CONNECT IS E4  RC AT  31
CONNECT IS E5  RC AT  34
CONNECT IS E6  RC AT  37
CONNECT IS E1  RC AT  45
CONNECT IS E1  RC AT  49
DEFAULT MLEVEL IS ATOM
GGCAT   IS LOC  SAT  AT  24
GGCAT   IS MCY  UNS  AT  25
GGCAT   IS MCY  UNS  AT  28
GGCAT   IS MCY  UNS  AT  31
GGCAT   IS MCY  UNS  AT  34
GGCAT   IS MCY  UNS  AT  37
GGCAT   IS LOC  SAT  AT  45
GGCAT   IS LOC  SAT  AT  46
GGCAT   IS LOC  SAT  AT  49
GGCAT   IS LOC  SAT  AT  51
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E6 C  AT  25
ECOUNT  IS E6 C  AT  28
```

```
ECOUNT  IS E6 C  AT  31
ECOUNT  IS E6 C  AT  34
ECOUNT  IS E6 C  AT  37

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  52

STEREO ATTRIBUTES: NONE
L8              STR
```




```
REP G1=(0-2) A
VAR G2=H/11/12
NODE ATTRIBUTES:
CONNECT IS E1  RC AT  11
DEFAULT MLEVEL IS ATOM
GGCAT   IS SAT  AT  11
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS UNLIMITED  AT   2  3  4

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  14

STEREO ATTRIBUTES: NONE
L12           3 SEA FILE=WPIX SSS FUL L1 AND L8
L13           2 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L12/DCR


=> dup rem l16 l13
FILE 'CAPLUS' ENTERED AT 14:31:00 ON 17 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 14:31:00 ON 17 DEC 2008
COPYRIGHT (C) 2008 THOMSON REUTERS
PROCESSING COMPLETED FOR L16
PROCESSING COMPLETED FOR L13
L17           4 DUP REM L16 L13 (2 DUPLICATES REMOVED)
                ANSWERS '1-4' FROM FILE CAPLUS

=> d l17 ibib abs hitstr tot

L17  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2008 ACS on STN  DUPLICATE 1
ACCESSION NUMBER:         2005:1126684  CAPLUS  Full-text
DOCUMENT NUMBER:          143:405806
TITLE:                    Preparation of piperidine derivatives for the
                          treatment of chemokine mediated diseases
INVENTOR(S):              Mochel, Tobias; Perry, Matthew; Springthorpe, Brian
PATENT ASSIGNEE(S):       Astrazeneca AB, Swed.
SOURCE:                   PCT Int. Appl., 57 pp.
                          CODEN: PIXXD2
```

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097775	A1	20051020	WO 2005-SE495	20050405
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1735298	A1	20061227	EP 2005-722310	20050405
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1964964	A	20070516	CN 2005-80018458	20050405
JP 2007532535	T	20071115	JP 2007-507274	20050405
IN 2006DN05542	A	20070803	IN 2006-DN5542	20060922
US 20080262037	A1	20081023	US 2007-599700	20070216
PRIORITY APPLN. INFO.:			SE 2004-925 A	20040406
			WO 2005-SE495 W	20050405

OTHER SOURCE(S): CASREACT 143:405806; MARPAT 143:405806
GI



I



II

AB Title compds. I [R1 = (un)substituted phenyl; W = O or bond; Q = H or OH; one of A, B, D, E and G = C-X-Y-CO2R5, another is CH or N and the others are CR2, CR3 and CR4; X = CH2, O, NH, or N-alkyl; Y = (un)substituted linking alkyl; R5 = H, alkyl, benzyl; R2-4 independently = H, halo, CN, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed for treatment of diseases mediated by chemokine (such as CCR3) or histamine receptors. Thus, e.g., II was prepared via hydrolysis of corresponding Me ester (preparation given). I were evaluated for binding to histamine H1 receptors, e.g., II

demonstrated a pKi value of 8.3. Assays for chemokine receptor activity were also described.

IT 867218-97-1P 867219-01-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of piperidine derivs. for the treatment of chemokine mediated diseases)

RN 867218-97-1 CAPLUS
CN Benzeneacetic acid, 3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 867219-01-0 CAPLUS
CN Acetic acid, 2-[2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 867218-98-2P 867218-99-3P 867219-00-9P
867219-02-1P 867219-03-2P 867219-04-3P
867219-05-4P 867219-06-5P 867219-07-6P
867219-08-7P 867219-09-8P 867219-10-1P
867219-11-2P 867219-12-3P 867219-13-4P
867219-14-5P 867219-15-6P 867219-16-7P
867219-17-8P 867219-18-9P 867219-19-0P
867219-20-3P 867219-22-5P 867219-23-6P
867219-24-7P 867219-25-8P 867219-26-9P
867219-27-0P 867219-28-1P 867219-29-2P
867219-30-5P 867219-31-6P 867219-32-7P
867219-33-8P 867219-34-9P 867219-35-0P
867219-36-1P 867219-37-2P 867219-38-3P
867219-40-7P 867219-41-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidine derivs. for the treatment of chemokine mediated diseases)

RN 867218-98-2 CAPLUS

CN Benzeneacetic acid, 2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 867218-99-3 CAPLUS

CN Benzeneacetic acid, 4-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 867219-00-9 CAPLUS

CN Benzeneacetic acid, 3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-methoxy-, methyl ester (CA INDEX NAME)



RN 867219-02-1 CAPLUS

CN Acetic acid, 2-[3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 867219-03-2 CAPLUS
CN Acetic acid, 2-[4-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 867219-04-3 CAPLUS
CN Propanoic acid, 2-[2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 867219-05-4 CAPLUS
CN Propanoic acid, 2-[2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, methyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 867219-06-5 CAPLUS
CN Propanoic acid, 2-[2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, methyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 867219-07-6 CAPLUS
CN Propanoic acid, 2-[3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, methyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 867219-08-7 CAPLUS
CN Propanoic acid, 2-[3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, methyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 867219-09-8 CAPLUS
CN Benzenepropanoic acid, 2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 867219-10-1 CAPLUS
CN Benzeneacetic acid, 4-[4-[[4-(3,4-dichloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 867219-11-2 CAPLUS
CN Benzeneacetic acid, 4-[4-[[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 867219-12-3 CAPLUS
CN Benzeneacetic acid, 3-[4-[[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 867219-13-4 CAPLUS
CN Benzeneacetic acid, 4-[4-[[4-(3-chloro-4-cyano-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 867219-14-5 CAPLUS
CN Propanoic acid, 2-[3-[4-[[4-(3-chloro-4-cyano-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, methyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 867219-15-6 CAPLUS
CN Benzeneacetic acid, 3-[4-[[4-(3,4-dichloro-2-ethylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 867219-16-7 CAPLUS
CN Benzeneacetic acid, 3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 867219-17-8 CAPLUS
CN Benzeneacetic acid, 2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 867219-18-9 CAPLUS
CN Benzeneacetic acid, 4-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 867219-19-0 CAPLUS
CN Benzeneacetic acid, 3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-methoxy- (CA INDEX NAME)



RN 867219-20-3 CAPLUS
CN Acetic acid, 2-[2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]- (CA INDEX NAME)



RN 867219-22-5 CAPLUS
CN Acetic acid, 2-[3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]- (CA INDEX NAME)



RN 867219-23-6 CAPLUS
CN Acetic acid, 2-[4-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]- (CA INDEX NAME)



RN 867219-24-7 CAPLUS
CN Propanoic acid, 2-[2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-2-methyl- (CA INDEX NAME)



RN 867219-25-8 CAPLUS
CN Propanoic acid, 2-[2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 867219-26-9 CAPLUS
CN Propanoic acid, 2-[2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 867219-27-0 CAPLUS
CN Propanoic acid, 2-[3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 867219-28-1 CAPLUS
CN Propanoic acid, 2-[3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 867219-29-2 CAPLUS
CN Benzenepropanoic acid, 2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 867219-30-5 CAPLUS
CN Benzeneacetic acid, 4-[4-[[4-(3,4-dichloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 867219-31-6 CAPLUS
CN Benzeneacetic acid, 4-[4-[[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 867219-32-7 CAPLUS
CN Benzeneacetic acid, 3-[4-[[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 867219-33-8 CAPLUS
CN Benzeneacetic acid, 4-[4-[[4-(3-chloro-4-cyano-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 867219-34-9 CAPLUS
CN Propanoic acid, 2-[3-[4-[[4-(3-chloro-4-cyano-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 867219-35-0 CAPLUS
CN Benzeneacetic acid, 3-[4-[[4-(3,4-dichloro-2-ethylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 867219-36-1 CAPLUS
CN Acetic acid, 2-[4-chloro-2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



RN 867219-37-2 CAPLUS
CN Acetic acid, 2-[2-chloro-6-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]- (CA INDEX NAME)



RN 867219-38-3 CAPLUS
CN Acetic acid, 2-[2-[4-[[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-methylphenoxy]- (CA INDEX NAME)



RN 867219-40-7 CAPLUS
CN Propanoic acid, 2-[3-[4-[[4-(3,4-dichloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]phenoxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 867219-41-8 CAPLUS
CN Benzeneacetic acid, 3-[4-[[4-(3,4-dichloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2004:996129 CAPLUS Full-text
DOCUMENT NUMBER: 141:424114
TITLE: Preparation of 1-aryl (aryloxy)- or (arylmethyl)piperidinemethylpiperidines as histamine H1 receptor binding agents for treatment of chemokine-mediated diseases
INVENTOR(S): Luckhurst, Christopher; Mochel, Tobias; Perry, Matthew; Springthorpe, Brian; Stein, Linda
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099144	A1	20041118	WO 2004-SE693	20040506
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1625114	A1	20060215	EP 2004-731523	20040506
EP 1625114	B1	20080827		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2006525996	T	20061116	JP 2006-508044	20040506
AT 406353	T	20080915	AT 2004-731523	20040506
US 20060264463	A1	20061123	US 2005-556107	20051108
PRIORITY APPLN. INFO.:			SE 2003-1368 A	20030509
			WO 2004-SE693 W	20040506

OTHER SOURCE(S): MARPAT 141:424114
GI



I



II

AB Compds. I [A, B, D, E, G = R5O2CC, R2C, HC, N; Q = H, HO; W = alkylimino, NH, O, H2C; X = (CH2)m; Y = (CH2)n; R1 = (un)substituted phenyl; R2 = H, halo, NC, alkyl, haloalkyl, alkoxy, haloalkoxy; R5 = H, alkyl, PhCH2; m, n = 0, 1] such as II are prepared as histamine H1 receptor binding agents for the treatment of chemokine-mediated diseases. E.g., reductive amination of 4-(3,4-dichlorophenoxy)piperidine with 1-Boc-4-formylpiperidine and sodium triacetoxyborohydride, cleavage of the Boc group with trifluoroacetic acid, and nucleophilic aromatic substitution of Me 2-fluorobenzoate with the aryloxypiperidinemethylpiperidine yields II. The pKi values for displacement of a ligand from human histamine H1 receptors are determined for some of the invention compds. E.g., II displaces a ligand from human histamine H1 receptors with a pKi value of 8.6. Methods for preparing the title compds. are claimed.

IT 796592-57-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(invention compound; preparation of 1-aryl (aryloxy)- or (arylmethyl)piperidinemethylpiperidines as histamine H1 receptor binding agents for treatment of chemokine-mediated diseases)

RN 796592-57-9 CAPLUS

CN Benzoic acid, 2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)

IT 796592-63-7P 796592-67-1P 796592-73-9P
796592-79-5P 796592-84-2P 796592-90-0P
796592-95-5P 796593-01-6P 796593-07-2P

796593-11-8P 796593-17-4P 796593-23-2P
796593-27-6P 796593-67-4P 796593-77-6P
796593-83-4P 796593-89-0P 796593-96-9P
796594-00-8P 796594-07-5P 796594-13-3P
796594-18-8P 796594-25-7P 796594-30-4P
796594-38-2P 796594-43-9P 796594-58-8P
796594-56-4P 796594-63-3P 796594-76-8P
796594-82-6P 796594-86-0P 796594-94-0P
796595-00-1P 796595-08-9P 796595-14-7P
796595-21-6P 796595-28-3P 796595-35-2P
796595-42-1P 796595-48-7P 796595-55-6P
796595-60-3P 796595-68-1P 796595-73-8P
796595-80-7P 796595-86-3P 796595-94-3P
796596-01-5P 796596-08-2P 796596-15-1P
796596-22-0P 796596-29-7P 796596-36-6P
796596-44-6P 796596-52-6P 796596-59-3P
796596-67-3P 796596-73-1P 796596-80-0P
796596-86-6P 796596-91-3P 796596-99-1P
796597-04-1P 796597-13-2P 796597-18-7P
796597-25-6P 796597-31-4P 796597-38-1P
796597-46-1P 796597-53-0P 796597-60-9P
796597-68-7P 796597-75-6P 796597-82-5P
796597-89-2P 796598-31-7P 796598-42-0P
796598-55-5P 796598-62-4P 796598-69-1P
796598-76-0P 796598-83-9P 796598-90-8P
796598-97-5P 796599-05-8P 796599-12-7P
796599-19-4P 796599-26-3P 796599-33-2P
796599-40-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(invention compound; preparation of 1-aryl (aryloxy)- or (arylmethyl)piperidinemethylpiperidines as histamine H1 receptor binding agents for treatment of chemokine-mediated diseases)

RN 796592-63-7 CAPLUS

CN Benzoic acid, 2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 796592-67-1 CAPLUS

CN Benzoic acid, 2-[4-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 796592-73-9 CAPLUS
CN Benzoic acid, 4-chloro-2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 796592-79-5 CAPLUS
CN Benzoic acid, 2-[4-[[4-(2-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 796592-84-2 CAPLUS
CN Benzoic acid, 4-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, ethyl ester (CA INDEX NAME)



RN 796592-90-0 CAPLUS
CN Benzoic acid, 4-chloro-2-[4-[[4-(2-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 796592-95-5 CAPLUS
CN Benzoic acid, 3-chloro-4-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 796593-01-6 CAPLUS
CN Benzoic acid, 2-chloro-4-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 796593-07-2 CAPLUS
CN Benzoic acid, 2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-methyl-, methyl ester (CA INDEX NAME)



RN 796593-11-8 CAPLUS
CN Benzoic acid, 2-[4-[[4-(4-chlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 796593-17-4 CAPLUS
CN Benzoic acid, 3-chloro-2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 796593-23-2 CAPLUS
CN Benzoic acid, 2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-4-hydroxy-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 796593-27-6 CAPLUS
CN Benzoic acid, 2-[4-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-1-piperidinyl]-4-methyl-, methyl ester (CA INDEX NAME)



RN 796593-67-4 CAPLUS
CN Benzoic acid, 2-[4-[[4-(3-chloro-4-cyano-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 796593-77-6 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 796593-83-4 CAPLUS
CN Benzoic acid, 3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, ethyl ester (CA INDEX NAME)



RN 796593-89-0 CAPLUS
CN Benzoic acid, 3-[4-[[4-(3,4-dichloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, ethyl ester (CA INDEX NAME)



RN 796593-96-9 CAPLUS
CN Benzoic acid, 3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 796594-00-8 CAPLUS
CN Benzoic acid, 4-chloro-3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 796594-07-5 CAPLUS
CN Benzoic acid, 3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 796594-13-3 CAPLUS
CN Benzoic acid, 3-[4-[[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 796594-18-8 CAPLUS
CN Benzoic acid, 2-chloro-5-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 796594-25-7 CAPLUS
CN 2-Pyridinecarboxylic acid, 6-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 796594-30-4 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 796594-38-2 CAPLUS
CN Benzoic acid, 3-[4-[[4-[(3,4-dichlorophenyl)methyl]-1-piperidinyl]methyl]-1-piperidinyl]-, ethyl ester (CA INDEX NAME)



RN 796594-43-9 CAPLUS
CN Benzoic acid, 2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796594-50-8 CAPLUS
CN Benzoic acid, 2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796594-56-4 CAPLUS
CN Benzoic acid, 2-[4-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796594-63-3 CAPLUS
CN Benzoic acid, 4-chloro-2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796594-76-8 CAPLUS
CN Benzoic acid, 4-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796594-82-6 CAPLUS
CN Benzoic acid, 4-chloro-2-[4-[[4-(2-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796594-86-0 CAPLUS
CN Benzoic acid, 3-chloro-4-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796594-94-0 CAPLUS
CN Benzoic acid, 2-chloro-4-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796595-00-1 CAPLUS
CN Benzoic acid, 2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-methyl- (CA INDEX NAME)



RN 796595-08-9 CAPLUS
CN Benzoic acid, 2-[4-[[4-(4-chlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-methyl- (CA INDEX NAME)



RN 796595-14-7 CAPLUS
CN Benzoic acid, 2-[4-[[4-(4-chlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796595-21-6 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-6-(trifluoromethyl)- (CA INDEX NAME)



RN 796595-28-3 CAPLUS
CN Benzoic acid, 2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-nitro- (CA INDEX NAME)



RN 796595-35-2 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-6-methyl- (CA INDEX NAME)



RN 796595-42-1 CAPLUS
CN Benzoic acid, 3-chloro-2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796595-48-7 CAPLUS
CN Benzoic acid, 2-[4-[[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796595-55-6 CAPLUS
CN Benzoic acid, 2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 796595-60-3 CAPLUS
CN Benzoic acid, 5-chloro-2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796595-68-1 CAPLUS
CN Benzoic acid, 2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-(trifluoromethyl)- (CA INDEX NAME)



RN 796595-73-8 CAPLUS
CN Benzoic acid, 2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-3-fluoro- (CA INDEX NAME)



RN 796595-80-7 CAPLUS
CN Benzoic acid, 2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-fluoro- (CA INDEX NAME)



RN 796595-86-3 CAPLUS
CN Benzoic acid, 2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-3-methoxy- (CA INDEX NAME)



RN 796595-94-3 CAPLUS
CN Benzoic acid, 2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-methyl- (CA INDEX NAME)



RN 796596-01-5 CAPLUS
CN Benzoic acid, 2-[4-[[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-3-fluoro- (CA INDEX NAME)



RN 796596-08-2 CAPLUS
CN Benzoic acid, 2-[4-[[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-(trifluoromethyl)- (CA INDEX NAME)



RN 796596-15-1 CAPLUS
CN Benzoic acid, 2-[4-[[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-nitro- (CA INDEX NAME)



RN 796596-22-0 CAPLUS
CN Benzoic acid, 2-[4-[[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-3-methoxy- (CA INDEX NAME)



RN 796596-29-7 CAPLUS
CN Benzoic acid, 2-[4-[[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-

piperidinyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 796596-36-6 CAPLUS
CN Benzoic acid, 4-chloro-2-[4-[[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796596-44-6 CAPLUS
CN Benzoic acid, 2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)



RN 796596-52-6 CAPLUS
CN Benzoic acid, 2-[4-[[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-fluoro- (CA INDEX NAME)



RN 796596-59-3 CAPLUS
CN Benzoic acid, 3-chloro-2-[4-[[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796596-67-3 CAPLUS
CN Benzoic acid, 5-chloro-2-[4-[[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796596-73-1 CAPLUS
CN Benzoic acid, 2-[4-[[4-(4-chloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 796596-80-0 CAPLUS
CN Benzoic acid, 2-[4-[[4-(4-chloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-3-fluoro- (CA INDEX NAME)



RN 796596-86-6 CAPLUS
CN Benzoic acid, 2-[4-[[4-(4-chloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-fluoro- (CA INDEX NAME)



RN 796596-91-3 CAPLUS
CN Benzoic acid, 2-[4-[[4-(4-chloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-(trifluoromethyl)- (CA INDEX NAME)



RN 796596-99-1 CAPLUS
CN Benzoic acid, 2-[4-[[4-(4-chloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-methyl- (CA INDEX NAME)



RN 796597-04-1 CAPLUS
CN Benzoic acid, 5-chloro-2-[4-[[4-(4-chloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796597-13-2 CAPLUS
CN Benzoic acid, 2-[4-[[4-(4-chloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-methyl- (CA INDEX NAME)



RN 796597-18-7 CAPLUS
CN Benzoic acid, 4-chloro-2-[4-[[4-(4-chloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796597-25-6 CAPLUS
CN Benzoic acid, 3-chloro-2-[4-[[4-(4-chloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796597-31-4 CAPLUS
CN Benzoic acid, 2-[4-[[4-(4-chloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-3-methoxy- (CA INDEX NAME)



RN 796597-38-1 CAPLUS
CN Benzoic acid, 2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-6-fluoro- (CA INDEX NAME)



RN 796597-46-1 CAPLUS
CN Benzoic acid, 2-[4-[[4-(3-chloro-4-cyanophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-methoxy- (CA INDEX NAME)



RN 796597-53-0 CAPLUS
CN Benzoic acid, 2-[4-[[4-[(3,4-dichlorophenyl)methyl]-1-piperidinyl]methyl]-1-piperidinyl]-5-methyl- (CA INDEX NAME)



RN 796597-60-9 CAPLUS
CN Benzoic acid, 2-[4-[[4-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-1-piperidinyl]-5-methyl- (CA INDEX NAME)



RN 796597-68-7 CAPLUS
CN Benzoic acid, 2-[4-[[4-[(4-chlorophenyl)methyl]-1-piperidinyl]methyl]-1-piperidinyl]-3-methoxy- (CA INDEX NAME)



RN 796597-75-6 CAPLUS
CN Benzoic acid, 2-[4-[[4-[(3,4-dichlorophenyl)methyl]-1-piperidinyl]methyl]-1-piperidinyl]-3-methoxy- (CA INDEX NAME)



RN 796597-82-5 CAPLUS
CN Benzoic acid, 2-[4-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-1-piperidinyl]-5-methyl- (CA INDEX NAME)



RN 796597-89-2 CAPLUS
CN Benzoic acid, 2-[4-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-1-piperidinyl]-3-methoxy- (CA INDEX NAME)



RN 796598-31-7 CAPLUS
CN Benzoic acid, 2-[4-[[4-(3-chloro-4-cyano-2-methylphenoxy)-1-

piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796598-42-0 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796598-55-5 CAPLUS
CN Benzoic acid, 3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796598-62-4 CAPLUS
CN Benzoic acid, 3-[4-[[4-(4-chlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796598-69-1 CAPLUS
CN Benzoic acid, 3-[4-[[4-(3,4-dichloro-2-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796598-76-0 CAPLUS
CN Benzoic acid, 3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-methyl- (CA INDEX NAME)



RN 796598-83-9 CAPLUS
CN Benzoic acid, 3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 796598-90-8 CAPLUS
CN Benzoic acid, 3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-5-methyl- (CA INDEX NAME)



RN 796598-97-5 CAPLUS
CN Benzoic acid, 4-chloro-3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796599-05-8 CAPLUS
CN Benzoic acid, 3-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-4-methoxy- (CA INDEX NAME)



RN 796599-12-7 CAPLUS
CN Benzoic acid, 3-[4-[[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796599-19-4 CAPLUS

CN Benzoic acid, 2-chloro-5-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796599-26-3 CAPLUS
CN 2-Pyridinecarboxylic acid, 6-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 796599-33-2 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 796599-40-1 CAPLUS
CN Benzoic acid, 3-[4-[[4-[(3,4-dichlorophenyl)methyl]-1-piperidinyl]methyl]-1-piperidinyl]- (CA INDEX NAME)



L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:171091 CAPLUS Full-text
DOCUMENT NUMBER: 148:369281
TITLE: Overcoming Undesirable hERG Potency of Chemokine Receptor Antagonists Using Baseline Lipophilicity Relationships
AUTHOR(S): Shamovsky, Igor; Connolly, Stephen; David, Laurent; Ivanova, Svetlana; Norden, Bo; Springthorpe, Brian; Urbahns, Klaus
CORPORATE SOURCE: Department of Medicinal Chemistry, AstraZeneca R & D Lund, Lund, S-22187, Swed.
SOURCE: Journal of Medicinal Chemistry (2008), 51(5), 1162-1178
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The inhibition of the hERG channel by noncardiovascular drugs is a side effect that severely impedes the development of new medications. To increase hERG selectivity of preclin. compds., the authors recommend the study of nondesolvation related interactions with the intended target and hERG using a baseline lipophilicity relationship approach. While this approach is conventionally used in studies of potency, the authors demonstrate here that it can help in selectivity issues. Studies of hERG selectivity in four inhouse classes of chemokine receptor (CCR) antagonists suggest that the selectivity is improved most effectively by structural alterations that increase the lipophilicity-adjusted primary potency, pIC50CCR - LogD. Fragment-based QSAR anal. is performed using the lipophilicity-adjusted hERG potency, pIC50hERG - LogD, to identify moieties that form nonhydrophobic interactions with the hERG channel. These moieties, which erode hERG selectivity, can then be avoided. A novel two-dimensional fragment-based QSAR anal. helps visualizing the lipophilicity-adjusted hERG and CCR potencies within chemical series.

IT 1013653-73-0D, derivs.
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(overcoming undesirable hERG potency of chemokine receptor antagonists using baseline lipophilicity relationships)
RN 1013653-73-0 CAPLUS
CN Benzoic acid, 2-[4-[(4-phenoxy-1-piperidinyl)methyl]-1-piperidinyl]- (CA INDEX NAME)



REFERENCE COUNT: 110 THERE ARE 110 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:292021 CAPLUS Full-text
DOCUMENT NUMBER: 140:303547

TITLE: Preparation of piperidine derivatives for use in the treatment of chemokine mediated disease states
INVENTOR(S): Luckhurst, Christopher; Perry, Matthew; Springthorpe, Brian
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029041	A1	20040408	WO 2003-SE1425	20030912
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497280	A1	20040408	CA 2003-2497280	20030912
AU 2003259004	A1	20040419	AU 2003-259004	20030912
AU 2003259004	B2	20070208		
EP 1546130	A1	20050629	EP 2003-798620	20030912
EP 1546130	B1	20070801		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014688	A	20050802	BR 2003-14688	20030912
CN 1684952	A	20051019	CN 2003-822502	20030912
JP 2006503066	T	20060126	JP 2004-539695	20030912
NZ 538527	A	20061027	NZ 2003-538527	20030912
EP 1816123	A1	20070808	EP 2007-10143	20030912
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR, AL, LT, LV, MK				
AT 368656	T	20070815	AT 2003-798620	20030912
ES 2289354	T3	20080201	ES 2003-798620	20030912
MX 2005PA03007	A	20050622	MX 2005-PA3007	20050317
ZA 2005002341	A	20050919	ZA 2005-2341	20050318
US 20060040984	A1	20060223	US 2005-528477	20050318
NO 2005001965	A	20050623	NO 2005-1965	20050422
PRIORITY APPLN. INFO.:			SE 2002-2838 A	20020924
			EP 2003-798620 A3	20030912
			WO 2003-SE1425 W	20030912

OTHER SOURCE(S): MARPAT 140:303547
GI



I



II

AB Title compds. I [X = CH2, CO, O, SO0-2, amino; Y = bond, alkylene, etc.; Z = carboxy, aminosulfonyl, etc.; R1-2 = H, alkyl, aryl, heterocyclyl; R4 = H, alkyl; R3 = H, OH] are prepared For instance, 4-[[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methyl]piperidine (preparation given) is reacted with glyoxylic acid and benzeneboronic acid (EtOH, microwave, 100°, 5 min) to give II. II has pKi = 7.2 for the H1 receptor. I are useful for the treatment of a chemokine (such as CCR3) or H1 mediated disease state.

IT 676517-94-5P, 2-[[4-[[4-(3,4-Dichlorophenoxy)piperidin-1-yl]methyl]piperidin-1-yl]-2,4-dimethoxypyrimidin-5-yl]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel piperidine derivs. for use in treatment of chemokine mediated disease states)

RN 676517-94-5 CAPLUS

CN 5-Pyrimidineacetic acid, 4-[4-[[4-(3,4-dichlorophenoxy)-1-piperidinyl]methyl]-1-piperidinyl]-2,6-dimethoxy- (CA INDEX NAME)



=> d his nofil

(FILE 'HOME' ENTERED AT 14:07:19 ON 17 DEC 2008)

```
     FILE 'REGISTRY' ENTERED AT 14:12:40 ON 17 DEC 2008
L1                STR
L2              6 SEA SSS SAM L1
L3            149 SEA SSS FUL L1

     FILE 'CAPLUS' ENTERED AT 14:21:56 ON 17 DEC 2008
L4              6 SEA SPE=ON  ABB=ON  PLU=ON  L3

     FILE 'REGISTRY' ENTERED AT 14:22:08 ON 17 DEC 2008
L5                STR
L6              0 SEA SUB=L3 SSS SAM L5
L7              0 SEA SUB=L3 SSS FUL L5
                  D QUE
L8                STR L5
L9              6 SEA SUB=L3 SSS SAM L8
L10           138 SEA SUB=L3 SSS FUL L8

     FILE 'WPIX' ENTERED AT 14:29:08 ON 17 DEC 2008
L11             0 SEA SSS SAM L1 AND L8
L12             3 SEA SSS FUL L1 AND L8
L13             2 SEA SPE=ON  ABB=ON  PLU=ON  L12/DCR

     FILE 'BEILSTEIN' ENTERED AT 14:29:37 ON 17 DEC 2008
L14             0 SEA SSS SAM L1 AND L8
L15             0 SEA SSS FUL L1 AND L8

     FILE 'CAPLUS' ENTERED AT 14:30:23 ON 17 DEC 2008
L16             4 SEA SPE=ON  ABB=ON  PLU=ON  L10

     FILE 'CAPLUS' ENTERED AT 14:30:46 ON 17 DEC 2008
                  D QUE L16

     FILE 'WPIX' ENTERED AT 14:30:53 ON 17 DEC 2008
                  D QUE L13

     FILE 'CAPLUS, WPIX' ENTERED AT 14:31:00 ON 17 DEC 2008
L17             4 DUP REM L16 L13 (2 DUPLICATES REMOVED)
                        ANSWERS '1-4' FROM FILE CAPLUS
                  D L17 IBIB ABS HITSTR TOT

=> d his

     (FILE 'HOME' ENTERED AT 14:07:19 ON 17 DEC 2008)

     FILE 'REGISTRY' ENTERED AT 14:12:40 ON 17 DEC 2008
L1                STR
L2              6 S L1
L3            149 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 14:21:56 ON 17 DEC 2008
L4              6 S L3

     FILE 'REGISTRY' ENTERED AT 14:22:08 ON 17 DEC 2008
L5                STR
L6              0 S L5 SAM SUB=L3
L7              0 S L5 FUL SUB=L3
L8                STR L5
L9              6 S L8 SAM SUB=L3
L10           138 S L8 FULL SUB=L3
```

```
     FILE 'WPIX' ENTERED AT 14:29:08 ON 17 DEC 2008
L11             0 S L1 AND L8
L12             3 S L1 AND L8 FUL
L13             2 S L12/DCR

     FILE 'BEILSTEIN' ENTERED AT 14:29:37 ON 17 DEC 2008
L14             0 S L1 AND L8
L15             0 S L1 AND L8 FUL

     FILE 'CAPLUS' ENTERED AT 14:30:23 ON 17 DEC 2008
L16             4 S L10

     FILE 'CAPLUS' ENTERED AT 14:30:46 ON 17 DEC 2008

     FILE 'WPIX' ENTERED AT 14:30:53 ON 17 DEC 2008

     FILE 'CAPLUS, WPIX' ENTERED AT 14:31:00 ON 17 DEC 2008
L17             4 DUP REM L16 L13 (2 DUPLICATES REMOVED)

=> fil reg
FILE 'REGISTRY' ENTERED AT 14:31:40 ON 17 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   16 DEC 2008  HIGHEST RN 1085590-90-4
DICTIONARY FILE UPDATES:  16 DEC 2008  HIGHEST RN 1085590-90-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d his

     (FILE 'HOME' ENTERED AT 14:07:19 ON 17 DEC 2008)

     FILE 'REGISTRY' ENTERED AT 14:12:40 ON 17 DEC 2008
L1                STR
L2              6 S L1
L3            149 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 14:21:56 ON 17 DEC 2008
L4              6 S L3

     FILE 'REGISTRY' ENTERED AT 14:22:08 ON 17 DEC 2008
L5                STR
L6              0 S L5 SAM SUB=L3
```

```
L7            0 S L5 FUL SUB=L3
L8              STR L5
L9            6 S L8 SAM SUB=L3
L10         138 S L8 FULL SUB=L3

     FILE 'WPIX' ENTERED AT 14:29:08 ON 17 DEC 2008
L11           0 S L1 AND L8
L12           3 S L1 AND L8 FUL
L13           2 S L12/DCR

     FILE 'BEILSTEIN' ENTERED AT 14:29:37 ON 17 DEC 2008
L14           0 S L1 AND L8
L15           0 S L1 AND L8 FUL

     FILE 'CAPLUS' ENTERED AT 14:30:23 ON 17 DEC 2008
L16           4 S L10

     FILE 'CAPLUS' ENTERED AT 14:30:46 ON 17 DEC 2008

     FILE 'WPIX' ENTERED AT 14:30:53 ON 17 DEC 2008

     FILE 'CAPLUS, WPIX' ENTERED AT 14:31:00 ON 17 DEC 2008
L17           4 DUP REM L16 L13 (2 DUPLICATES REMOVED)

     FILE 'REGISTRY' ENTERED AT 14:31:40 ON 17 DEC 2008
```